Compare Pancaran Samudera Transport Tbk. (PSAT) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pancaran Samudera Transport Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Pancaran Samudera Transport Tbk. trades at Rp880 (market cap 1.32T, 51.1K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Pancaran Samudera Transport Tbk. is far larger — about 12.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PSAT | SCPI | |
|---|---|---|
Market Cap | 1.32T | 104.4B |
Volume | 51.1K | — |
Lot | 511 | — |
Turnover | 45.29M | — |
Average Price | 886.35 | — |
Value | 45.29M | — |
Indicative Equilibrium Price | 880 | — |
Indicative Equilibrium Volume | 5 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pancaran Samudera Transport Tbk.
PT Pancaran Samudera Transport Tbk (the Company) was established on December 10, 2007 in the Republic of Indonesia based on the Notarial Deed No. 1 from Mary Maria, S.H, Notary in Depok. The Company commenced its operations in 2007. The Companys immediate parent company is PT Profitama Hasil Indah, incorporated and domiciled in Indonesia and its ultimate parent company is PT Pancaran Harapan Integra, also incorporated and domiciled in Indonesia.
Read more on PSAT →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
